Maravai Historical Balance Sheet
MRVI Stock | USD 4.77 0.20 4.38% |
Trend analysis of Maravai Lifesciences Holdings balance sheet accounts such as Total Current Liabilities of 89.4 M provides information on Maravai Lifesciences' total assets, liabilities, and equity, which is the actual value of Maravai Lifesciences to its prevalent stockholders. By breaking down trends over time using Maravai Lifesciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Maravai Lifesciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Maravai Lifesciences is a good buy for the upcoming year.
Maravai Lifesciences Inventory |
|
Maravai |
About Maravai Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Maravai Lifesciences at a specified time, usually calculated after every quarter, six months, or one year. Maravai Lifesciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Maravai Lifesciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Maravai currently owns. An asset can also be divided into two categories, current and non-current.
Maravai Lifesciences Balance Sheet Chart
Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Maravai Lifesciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Maravai Lifesciences Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Maravai Lifesciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Maravai Lifesciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. As of now, Maravai Lifesciences' Non Current Assets Total are increasing as compared to previous years. The Maravai Lifesciences' current Non Currrent Assets Other is estimated to increase to about 19.9 M, while Total Assets are projected to decrease to under 1.5 B.
2022 | 2023 | 2024 | 2025 (projected) | Short and Long Term Debt Total | 585.3M | 611.0M | 702.6M | 559.4M | Total Assets | 2.3B | 1.5B | 1.7B | 1.5B |
Maravai Lifesciences balance sheet Correlations
Click cells to compare fundamentals
Maravai Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Maravai Lifesciences balance sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 1.3B | 1.9B | 2.3B | 1.5B | 1.7B | 1.5B | |
Short Long Term Debt Total | 590.8M | 534.3M | 585.3M | 611.0M | 702.6M | 559.4M | |
Other Current Liab | 40.8M | 64.3M | 88.3M | 59.5M | 68.5M | 55.1M | |
Total Current Liabilities | 130.8M | 93.8M | 110.1M | 87.5M | 100.6M | 89.4M | |
Total Stockholder Equity | 88.5M | 315.5M | 545.2M | 416.8M | 479.3M | 302.8M | |
Other Liab | 15.9M | 400.4M | 713.6M | 693.4M | 797.4M | 405.2M | |
Net Tangible Assets | (280.7M) | (313.4M) | 315.5M | 44.9M | 51.6M | 54.2M | |
Property Plant And Equipment Net | 101.3M | 46.3M | 116.6M | 222.6M | 256.0M | 268.8M | |
Current Deferred Revenue | 78.1M | 10.2M | 3.1M | 3.4M | 3.0M | 2.9M | |
Net Debt | 354.6M | (17.0M) | (46.9M) | 36.0M | 32.4M | 30.8M | |
Retained Earnings | 854K | 184.6M | 404.8M | 285.7M | 328.6M | 345.0M | |
Accounts Payable | 3.0M | 8.2M | 6.0M | 10.7M | 12.3M | 7.1M | |
Cash | 236.2M | 551.3M | 632.1M | 575.0M | 661.2M | 374.2M | |
Non Current Assets Total | 939.1M | 1.2B | 1.4B | 787.5M | 905.7M | 979.4M | |
Non Currrent Assets Other | 4.2M | 52.9M | 40.3M | 9.3M | 10.7M | 19.9M | |
Other Assets | 805K | 435.9M | 812.5M | 806.1M | 927.0M | 973.4M | |
Long Term Debt | 528.6M | 524.6M | 522.0M | 518.7M | 596.5M | 506.8M | |
Cash And Short Term Investments | 236.2M | 551.3M | 632.1M | 575.0M | 661.2M | 374.2M | |
Net Receivables | 51.0M | 117.5M | 146.8M | 55.7M | 64.1M | 74.3M | |
Liabilities And Stockholders Equity | 1.3B | 1.9B | 2.3B | 1.5B | 1.7B | 1.5B | |
Non Current Liabilities Total | 985.2M | 1.3B | 1.3B | 610.1M | 701.6M | 898.5M | |
Capital Lease Obligations | 56.2M | 3.7M | 57.8M | 86.8M | 99.8M | 104.8M | |
Inventory | 33.3M | 51.6M | 43.2M | 51.4M | 59.1M | 38.1M | |
Other Current Assets | 11.1M | 19.7M | 25.8M | 17.8M | 20.5M | 14.6M | |
Other Stockholder Equity | 85.1M | 128.4M | 137.9M | 128.5M | 147.8M | 90.2M | |
Total Liab | 1.1B | 1.4B | 1.4B | 697.6M | 802.2M | 987.9M | |
Net Invested Capital | 623.1M | 846.1M | 1.1B | 940.9M | 1.1B | 814.7M | |
Property Plant And Equipment Gross | 101.3M | 46.3M | 136.1M | 254.9M | 293.1M | 307.7M | |
Total Current Assets | 331.6M | 740.0M | 847.9M | 699.9M | 804.9M | 501.2M | |
Capital Stock | 2.6M | 2.6M | 2.6M | 2.5M | 2.3M | 2.1M | |
Non Current Liabilities Other | 2.2M | 754.5M | 17.4M | 2.4M | 2.8M | 2.6M | |
Net Working Capital | 200.8M | 646.3M | 737.8M | 612.4M | 704.3M | 411.8M | |
Short Term Debt | 10.6M | 9.7M | 11.7M | 12.9M | 14.8M | 9.2M | |
Intangible Assets | 177.7M | 117.6M | 216.7M | 221.0M | 254.1M | 210.6M | |
Common Stock | 2.6M | 2.6M | 2.6M | 2.5M | 2.3M | 2.1M | |
Property Plant Equipment | 94.3M | 101.3M | 46.3M | 116.6M | 134.1M | 88.2M |
Currently Active Assets on Macroaxis
BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin | |
ADA | Cardano | |
XRP | XRP |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.74) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.